Lung Cancer, Nonsmall Cell Clinical Trials
2 recruiting trials for Lung Cancer, Nonsmall Cell. Eligibility criteria explained in plain English.
TrialFinderData lists 2 Lung Cancer, Nonsmall Cell clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Research is led by Cofactor Genomics, Inc. (1), Dutch Society of Physicians for Pulmonology and Tuberculosis (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is OncoPrism™ assay (diagnostic_test, 1 trial), followed by Health-related quality of life and treatment outcome questionnaires, (Tumor) tissue and other biomaterials.
Track Lung Cancer, Nonsmall Cell trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
A Multicenter Cancer Biospecimen Collection Study
This study will collect de-identified tumor samples, with correlated clinical/demographic data and tissue histology, from patients selected or scheduled for pre-treatment tumor...
Prospective Data Collection Initiative on Thoracic Malignancies
Survival after cancer diagnosis strongly depends on local tumor extent, lymph node involvement and the presence of distant metastases. However, there remains great inter-patient...
Explore Other Conditions
Frequently Asked Questions
There are currently 2 clinical trials for Lung Cancer, Nonsmall Cell, with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Lung Cancer, Nonsmall Cell, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Lung Cancer, Nonsmall Cell, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.